The Food and Drug Administration approved Alnylam’s drug to treat a rare and deadly heart disease on Thursday, allowing the entry of a new type of medicine in a market dominated by Pfizer’s blockbuster Vyndaqel. Alnylam is banking on the success of the drug, chemically called vutrisiran, to reach profitability and invest in future treatments. […]